Y Ohsugi

3.7k total citations · 1 hit paper
38 papers, 3.1k citations indexed

About

Y Ohsugi is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Y Ohsugi has authored 38 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 12 papers in Immunology and 7 papers in Oncology. Recurrent topics in Y Ohsugi's work include Monoclonal and Polyclonal Antibodies Research (6 papers), Systemic Lupus Erythematosus Research (5 papers) and T-cell and B-cell Immunology (5 papers). Y Ohsugi is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), Systemic Lupus Erythematosus Research (5 papers) and T-cell and B-cell Immunology (5 papers). Y Ohsugi collaborates with scholars based in Japan, United States and United Kingdom. Y Ohsugi's co-authors include Yasuo Koishihara, Tetsuya Taga, Masahiko Mihara, H Fukui, Takuro Saito, Masashi Narazaki, T Kishimoto, GD Yancopoulos, Yoshiki Yamada and Kenji Kumaki and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

In The Last Decade

Y Ohsugi

36 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

1993 700 citations T Tamura, Nobuyuki Udagawa et al. Proceedings of the National Academy of Sciences profile →

Peers

Countries citing papers authored by Y Ohsugi

Since Specialization

Citations

This map shows the geographic impact of Y Ohsugi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y Ohsugi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y Ohsugi more than expected).

Fields of papers citing papers by Y Ohsugi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y Ohsugi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y Ohsugi. The network helps show where Y Ohsugi may publish in the future.

Co-authorship network of co-authors of Y Ohsugi

This figure shows the co-authorship network connecting the top 25 collaborators of Y Ohsugi. A scholar is included among the top collaborators of Y Ohsugi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y Ohsugi. Y Ohsugi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Analysis of gene expression changes during lipid droplet formation in HepG2 human liver cancer cells 2024 ·PubMed ·Mitsuru Chiba, Y Ohsugi, (unknown), (unknown)	0
2	Intra-individual polymorphisms in the mitochondrial COI gene of tick-killing Ixodiphagus wasps parasitizing Haemaphysalis flava ticks 2024 ·Acta Tropica ·(unknown), (unknown), (unknown), (unknown), Yuma Ohari, Mackenzie L. Kwak, Seiki Baba, (unknown), (unknown), Y Ohsugi, (unknown), (unknown), Shohei Ogata, Keita Matsuno, Nariaki Nonaka, Ryo Nakao	0
3	Serum miR‑29 is increased in mice with early liver fibrosis 2024 ·Experimental and Therapeutic Medicine ·(unknown), Y Ohsugi, (unknown), (unknown), Yumiko Kato, (unknown), Mitsuru Chiba	3
4	Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis 2009 ·Lara D. Veeken ·Takeru Yoshimura, Koh‐Hei Sonoda, Nobuyuki Ohguro, Y Ohsugi, Tatsuro Ishibashi, (unknown), Takashi Kobayashi, Hideyuki Yoshida, Akihiko Yoshimura	166
5	Blockade of interleukin‐6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury 2004 ·Journal of Neuroscience Research ·Seiji Okada, Masaya Nakamura, Yuji Mikami, Takuya Shimazaki, Masahiko Mihara, Y Ohsugi, Yukihide Iwamoto, Kazuyuki Yoshizaki, Tadamitsu Kishimoto, Y. Toyama, Hideyuki Okano	209
6	Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy 1999 ·British Journal of Cancer ·Shin‐ichi Tsunoda, Iwao Ohizumi, Junji Matsui, Keiichi Koizumi, (unknown), Hiroo Makimoto, Yasuo Tsutsumi, Naoki Utoguchi, Kenji Taniguchi, Hiroyuki Saito, Naoki Harada, Y Ohsugi, Tadanori Mayumi	12
7	Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. 1996 ·Journal of Clinical Investigation ·Toshimasa Tsujinaka, Junya Fujita, Chikara Ebisui, M. Yano, Eiki Kominami, Koichi Suzuki, K Tanaka, Asako Katsume, Y Ohsugi, Hitoshi Shiozaki, Morito Monden	343
8	Role of Interleukin-6 in Skeletal Muscle Protein Breakdown and Cathepsin Activity in vivo 1996 ·European Surgical Research ·Junya Fujita, Toshimasa Tsujinaka, Chikara Ebisui, M. Yano, Hitoshi Shiozaki, Asako Katsume, Y Ohsugi, Morito Monden	30
9	Muscle Undergoes Atrophy in Association with Increase of Lysosomal Cathepsin Activity in Interleukin-6 Transgenic Mouse 1995 ·Biochemical and Biophysical Research Communications ·Toshimasa Tsujinaka, Chikara Ebisui, Junya Fujita, (unknown), Takeshi Morimoto, Atsuhiro Ogaẃa, Asako Katsume, Y Ohsugi, Eiki Kominami, Morito Monden	121
10	INTERLEUKIN-6 (IL-6) INDUCES THE PROLIFERATION OF SYNOVIAL FIBROBLASTIC CELLS IN THE PRESENCE OF SOLUBLE IL-6 RECEPTOR 1995 ·Lara D. Veeken ·Masahiko Mihara, Yoichiro Moriya, Tadamitsu Kishimoto, Y Ohsugi	176
11	Effects of Combined Antigrowth Factor Receptor Treatment on In Vitro Growth of Multiple Myeloma 1994 ·JNCI Journal of the National Cancer Institute ·Raymond Taetle, (unknown), Y Ohsugi, (unknown), Yoshiki Yamada, H. A. Messner, William S. Dalton	15
12	Interleukin-6 cDNA transfected Lewis lung carcinoma cells show unaltered net tumour growth rate but cause weight loss and shortened survival in syngeneic mice 1993 ·British Journal of Cancer ·Yuichiro Ohe, (unknown), K J Olsen, Yuki Miyahara, Koh Miura, Hitoshi Saitô, Yasuo Koishihara, Y Ohsugi, Tetsuya Ohira, Kazuto Nishio, Nagahiro Saijo	67
13	Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. breakdown → 1993 ·Proceedings of the National Academy of Sciences ·T Tamura, Nobuyuki Udagawa, N. Takahashi, Chisato Miyaura, Sakae Tanaka, Yoshiki Yamada, Yasuo Koishihara, Y Ohsugi, Kenji Kumaki, Tetsuya Taga	700
14	Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130 1993 ·Blood ·Masashi Narazaki, (unknown), Takuro Saito, Y Ohsugi, H Fukui, Yasuo Koishihara, GD Yancopoulos, Tetsuya Taga, T Kishimoto	322
15	Lobenzarit Disodium (CCA) Inhibits in Vitro Immunoglobulin Production via Direct Interaction with B Lymphocytes. 1992 ·Chemical and Pharmaceutical Bulletin ·Yasuaki Takeda, (unknown), Atsushi Sakamoto, Toshiaki Nakano, Yohei Sugawara, Y Ohsugi, Maiko Morita, Taissa M. Kasahara	1
16	Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA. 1992 ·PubMed ·Yoshiaki Okuno, Takayuki Takahashi, Akira Suzuki, M Fukumoto, Kimihito Nakamura, Hirokazu Fukui, Yasuo Koishihara, Y Ohsugi, Hiroo Imura	18
17	Anti-murine IL-6 receptor antibody inhibits IL-6 effects in vivo 1991 ·Immunology Letters ·Hiroshi Suzuki, Kiyoshi Yasukawa, Takashi Saito, Masayuki Anzai, Ryo Goitsuka, Atsuhiko Hasegawa, Y Ohsugi, Tetsuya Taga, Tadamitsu Kishimoto	11
18	Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies 1991 ·The Journal of Immunology ·Takashi Saito, Kiyoshi Yasukawa, Hiroshi Suzuki, (unknown), (unknown), (unknown), Yasuo Koishihara, H Fukui, Y Ohsugi, Hideo Yawata	54
19	Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation. 1989 ·PubMed ·Masahiko Mihara, Y Ohsugi	6
20	Studies of congenitally immunologic mutant New Zealand mice. III. Growth of B lymphocyte clones in congenitally athymic (nude) and hereditarily asplenic (Dh/+) NZB mice: a primary B cell defect. 1979 ·The Mouseion at the JAXlibrary (Jackson Laboratory) ·Y Ohsugi, M. Eric Gershwin	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact